Tenaya Therapeutics, Inc. financial data

Symbol
TNYA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
171 Oyster Point Blvd., Suite 500, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 616 % -28.7%
Debt-to-equity 18 % +23.7%
Return On Equity -76.4 % -35%
Return On Assets -64.8 % -31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78.5 M shares +17.4%
Common Stock, Shares, Outstanding 68.3 M shares +2.2%
Entity Public Float 272 M USD +73.5%
Common Stock, Value, Issued 8 K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 81 M shares +10.8%
Weighted Average Number of Shares Outstanding, Diluted 81 M shares +10.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 97.5 M USD +1.56%
General and Administrative Expense 33.7 M USD +4.79%
Operating Income (Loss) -131 M USD -2.37%
Nonoperating Income (Expense) 6.66 M USD +73.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -125 M USD -0.18%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -125 M USD -0.18%
Earnings Per Share, Basic -1.65 USD/shares +32.4%
Earnings Per Share, Diluted -1.65 USD/shares +32.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.3 M USD -18.3%
Marketable Securities, Current 115 M USD -29.6%
Cash, Cash Equivalents, and Short-term Investments 122 M USD -29.6%
Other Assets, Current 1.41 M USD
Assets, Current 129 M USD -16.8%
Property, Plant and Equipment, Net 41.4 M USD -16.1%
Operating Lease, Right-of-Use Asset 9.18 M USD -15.9%
Other Assets, Noncurrent 5.63 M USD +21.5%
Assets 185 M USD -24.6%
Accounts Payable, Current 6.66 M USD -10.4%
Accrued Liabilities, Current 8.44 M USD +3.56%
Liabilities, Current 19.2 M USD -0.76%
Operating Lease, Liability, Noncurrent 7.3 M USD -29.7%
Other Liabilities, Noncurrent 259 K USD +10.7%
Liabilities 26.7 M USD -10.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -120 K USD 0%
Retained Earnings (Accumulated Deficit) -436 M USD -40.1%
Stockholders' Equity Attributable to Parent 158 M USD -26.6%
Liabilities and Equity 185 M USD -24.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.7 M USD +5.38%
Net Cash Provided by (Used in) Financing Activities 46.8 M USD
Net Cash Provided by (Used in) Investing Activities -4.49 M USD -156%
Common Stock, Shares Authorized 1 B shares 0%
Common Stock, Shares, Issued 68.3 M shares +2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 13.6 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60 M USD -17.8%
Deferred Tax Assets, Valuation Allowance 101 M USD +42.4%
Deferred Tax Assets, Gross 104 M USD +41.3%
Operating Lease, Liability 11.4 M USD -19.5%
Payments to Acquire Property, Plant, and Equipment 564 K USD -10.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -125 M USD -0.6%
Lessee, Operating Lease, Liability, to be Paid 14.7 M USD -20.9%
Property, Plant and Equipment, Gross 67.9 M USD +1.07%
Operating Lease, Liability, Current 4.06 M USD +8.95%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.39 M USD -43.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.45 M USD -37.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.32 M USD -25.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43 M USD +3.03%
Deferred Tax Assets, Operating Loss Carryforwards 52.8 M USD +27.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200 M shares 0%
Unrecognized Tax Benefits 4.52 M USD +43.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47 M USD +3.01%
Operating Lease, Payments 1.33 M USD +1.29%
Additional Paid in Capital 594 M USD +12.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.16 M USD +1.17%
Deferred Tax Assets, Net of Valuation Allowance 3.04 M USD +12.8%
Share-based Payment Arrangement, Expense 16 M USD +24.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%